Jorge Santos da Silva compensation by year
MoonLake Immunotherapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $586,333 | $698,245 | $762,386 |
| Bonus | $589,819 | $574,254 | $0 |
| Stock awards | $0 | $0 | $4,000,021 |
| Option awards | $0 | $0 | $0 |
| Non-equity incentive | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $109,913 | $155,880 |
| All other | $22,063 | $23,626 | $24,922 |
| Total | $1,198,215 | $1,406,038 | $4,943,209 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MoonLake Immunotherapeutics DEF 14A filed April 21, 2026, accession 0001140361-26-015916, and prior-year filings. Open the filing on EDGAR.
How this page was built: the MoonLake Immunotherapeutics filed document, accession 0001140361-26-015916. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 95,763 | $1,262,156 | — |
| RSU | 7,401 | $97,545 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in MoonLake Immunotherapeutics's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2025 proxy (filed April 21, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-07-10 | Sale | 10b5-1 | 68,289 | $20.02 | 2,774,893 |
| 2026-07-09 | Sale | 10b5-1 | 33,936 | $20.01 | 2,843,182 |
| 2026-07-01 | Sale | 10b5-1 | 47,775 | $20.03 | 2,877,118 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
MoonLake Immunotherapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jorge Santos da Silva · this page | Chief Executive Officer; Interim Chair of the Board | $4,943,209 |
| Kristian Reich | Chief Scientific Officer | $4,795,493 |
| Matthias Bodenstedt | Chief Financial Officer | $4,692,576 |
Board service
MoonLake Immunotherapeutics board · FY2022–FY2025How this board is paid
Company policy: MoonLake Immunotherapeutics pays directors a $40,000 cash retainer and $224,349 in equity. As stated in MoonLake Immunotherapeutics's FY2025 proxy.
The full MoonLake Immunotherapeutics compensation record
free company briefThis page is one person within MoonLake Immunotherapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the MoonLake Immunotherapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order MoonLake Immunotherapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MoonLake Immunotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order MLTX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.